Document is current
Any future updates will be listed below
-
Authors
Nawas, Afshan Fathima
Solmonson, Ashley
Gao, Boning
DeBerardinis, Ralph J.
Minna, John D.
Conacci-Sorrell, Maralice
Mendelson, Carole R.
-
Funding
Funding for this research was provided by:
Division of Cancer Prevention, National Cancer Institute (NCI R35CA220449, R01CA245548)
Cancer Prevention and Research Institute of Texas (RP220046)
American Cancer Society (724003)
Welch Foundation (I-2058-20210327)
National Institutes of Health (GM145744-01)
NIH (R01-HL050022)
- License Information
-
More Information
Article History
Received: 12 August 2023
Accepted: 2 October 2023
First Online: 20 November 2023
Declarations
:
: RJD is a scientific advisor for Agios Pharmaceuticals, Nirogy Therapeutics, Vida Ventures and Droia Ventures, and a founder and advisor for Atavistik Bioscience. JDM receives royalties from the NIH and UTSW for distribution of human cell lines.
